| scholarly article | Q13442814 |
| P50 | author | Chang-Seok Ki | Q38641833 |
| P2093 | author name string | Kyoung-Mee Kim | |
| Ho Yeong Lim | |||
| Se Hoon Park | |||
| Sung Kim | |||
| Jeeyun Lee | |||
| Joon Oh Park | |||
| Won Ki Kang | |||
| Young Suk Park | |||
| Hyun Jung Jun | |||
| Jae Moon Bae | |||
| Min Gew Choi | |||
| Tae Sung Sohn | |||
| Ji-Youn Kim | |||
| Jae Hyung Noh | |||
| Jin Won Seo | |||
| Hey-Lim Jang | |||
| P433 | issue | 6 | |
| P304 | page(s) | 1517-1524 | |
| P577 | publication date | 2011-03-18 | |
| P1433 | published in | Oncology Reports | Q7092098 |
| P1476 | title | Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. | |
| P478 | volume | 25 |
| Q37268013 | A long non-coding RNA signature to improve prognosis prediction of gastric cancer |
| Q37222790 | A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies |
| Q54390371 | A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. |
| Q38732700 | Advances of Molecular Targeted Therapy in Gastric Cancer |
| Q34445648 | Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization |
| Q38238603 | Assessing adaptation of the cancer kinome in response to targeted therapies |
| Q89875046 | Bayesian Framework for Detecting Gene Expression Outliers in Individual Samples |
| Q26751332 | Biomarker development in MET-targeted therapy |
| Q38184380 | Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? |
| Q35041171 | C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis |
| Q35976337 | Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer |
| Q54260230 | Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. |
| Q38263841 | Clinical management of advanced gastric cancer: the role of new molecular drugs. |
| Q90353134 | Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy |
| Q26776190 | Clinical significance of MET in gastric cancer |
| Q37342442 | Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis |
| Q61443519 | Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial |
| Q48379063 | Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. |
| Q39245971 | Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer |
| Q47564950 | Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. |
| Q31121236 | Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells |
| Q54218339 | Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. |
| Q46815880 | FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation |
| Q35933994 | Frequent gene amplification predicts poor prognosis in gastric cancer |
| Q26741859 | Gastric biomarkers: a global review |
| Q38527414 | Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. |
| Q37591176 | Gastric cancer-molecular and clinical dimensions |
| Q58573393 | Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells |
| Q36646078 | High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma |
| Q51762437 | High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. |
| Q35181361 | Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. |
| Q55285319 | Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors. |
| Q36984821 | MET amplification as a potential therapeutic target in gastric cancer. |
| Q35666332 | MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib |
| Q42317509 | MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon |
| Q37597858 | MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy |
| Q36554574 | MET in gastric cancer--discarding a 10% cutoff rule |
| Q36089948 | MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome |
| Q34977222 | MET-Amplified Intramucosal Gastric Cancer Widely Metastatic after Complete Endoscopic Submucosal Dissection |
| Q38675350 | MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. |
| Q99408661 | Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer |
| Q37245714 | Molecular diagnosis for personalized target therapy in gastric cancer |
| Q38074157 | Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? |
| Q38019657 | Novel targeted agents for gastric cancer |
| Q97681268 | PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer |
| Q36661984 | Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. |
| Q27320322 | Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer |
| Q36638061 | Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy |
| Q27027981 | Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis |
| Q37565309 | Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review). |
| Q41640117 | SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1. |
| Q35051588 | Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors |
| Q38731943 | Targeted therapies in gastric cancer treatment: where we are and where we are going. |
| Q27008274 | Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome |
| Q36294579 | Targeted therapy in gastroesophageal cancers: past, present and future |
| Q34309927 | Targeting MET Amplification as a New Oncogenic Driver. |
| Q44826887 | Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer |
| Q55069791 | The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. |
| Q36127679 | The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays |
| Q36752744 | The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer |
| Q53562884 | The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR. |
| Q34661367 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives |
| Q41660598 | Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. |
| Q37962905 | c-MET as a potential therapeutic target and biomarker in cancer |
Search more.